Soft-tissue myoepithelioma (STM) is an extremely rare benign tumor with predominant occurrence in head, neck, pelvic girdle and limbs. These tumors lack specific clinical and morphological features and can easily be confused with more common neoplasms. It may lead to incorrect diagnosis and management. Here, we present a clinical case of a young man with retroperitoneal STM which simulated a pancreatic tumor and required a distal pancreatectomy. Performed literature review highlights current data about clinical, morphologic, immunohistochemical and genetic evaluation, treatment and prognosis of STM.
Introduction
Myoepithelioma is a rare benign tumor originating from ectodermally derived myoepithelial cells, which are mostly represented in exocrine glands between the acinar sinus and intercalated duct [1, 2] . Typically it occurs in salivary, sweat, lacrimal and mammary glands, but incidentally can be found in soft tissues, bones and viscera [3] [4] [5] . When this neoplasm presents in soft tissues close to organs, it might be incorrectly diagnosed as another primary tumors, which are more common for those locations. It leads to misdiagnosis contributing to errors in appropriate treatment. We report a clinical case of a retroperitoneal soft-tissue myoepithelioma (STM) which simulated a primary pancreatic tumor.
Case Report
A 39-year-old Caucasian man presented with a 1-month history of decreased appetite, mild abdominal pain and palpable epigastric abdominal mass. He was a lifelong nonsmoker with no significant past medical or family history. Computed tomography (CT) scan revealed a large epigastric mass (14 × 11 × 11 cm) growing from the pancreas with dislocated stomach, duodenum and left-sided portal hypertension ( Fig. 1 ). Positron emission tomography-CT (PET-CT) with F-18 fluorodeoxyglucose (F-18 FDG) showed patchy tracer uptake of the tumor located in the pancreatic body and tail ( Fig. 2 ). There was no evidence of regional or distant disease and all blood tests were within normal limits. Upper endoscopy with transluminal ultrasound-guided biopsy was performed. Final pathology suggested pancreatic myoepithelioma.
The patient underwent distal pancreatectomy. Intraoperatively, there was tumor compression of the superior mesenteric vein (SMV) and splenic vein junction with left-sided portal hypertension and severe inflammatory reaction of adjacent tissues. These findings were suspicious for malignant behavior of the neoplasm and led to technical difficulties. Complete removal of the mass required distal pancreatectomy and splenectomy, with estimated blood loss 2,800 mL. The patient recovered uneventfully and was discharged on the seventh postoperative day.
Postoperative pathology revealed a well-defined multinodal neoplasm with chondroid stroma and monotonous spindle cells having a co-expression of CAM5.2, smooth muscle actin (SMA) and S-100 protein (Figs. [3] [4] [5] [6] . The retroperitoneal STM was adjacent to pancreas without true invasion. The multidisciplinary tumor board recommended a 3 -6 months follow-up with imaging for 2 years and annual examination for the next 3 years.
At 15 months follow-up, the patient is asymptomatic without signs of malnutrition, malabsorption, or recurrence.
Discussion
This patient had retroperitoneal STM which was presumed to be a primary pancreatic tumor. Generally, myoepithelioma is a rare glandular tumor that is typically found in salivary glands Nikiforchin et al J Med Cases. 2020;11(1):16-21 [2, 5, 6] . Rarely it occurs in soft tissues with predominant growth in head and neck, pelvic girdle and limbs, where it usually appears as a palpable subcutaneous or subfascial painful or painless mass [3, 7] . There are few reported cases of non-typical sites like orbit, mediastinum, abdominal wall, mesentery and ovary [8] [9] [10] [11] [12] . Retroperitoneal space is an extremely uncommon localization for this tumor, described in single publications [13] . Retroperitoneal Soft-Tissue Myoepithelioma J Med Cases. 2020;11(1):16-21
The diagnosis of STM may be difficult due to lack of specific clinical and imaging guidelines. Some authors consider that moderate enhancement and well-defined cystic compo-nent of tumor on both CT and magnetic resonance imaging may be representative imaging characteristics for STM [10] . This is consistent with CT and PET-CT findings in our clinical 1 and 2 ). However, these traits are not truly specific and seen in a variety of other neoplasms, such as pancreatic and gastrointestinal stromal tumors (GISTs), as well as in sarcomas. Thus, a confirmed histopathologic diagnosis prior to treatment is needed to best guide clinical management. Core needle-guided biopsy is the preferred diagnostic method for pancreatic tumors due to its high accuracy and low complication rate [14] . The patient underwent upper endoscopy with transluminal ultrasound-guided biopsy of the tumor, which surprisingly confirmed benign myoepithelioma. Nevertheless, this preliminary diagnosis of STM seemed unlikely due to the uncommon localization and well-known difficulties of morphological evaluation.
Pathology examination of STM is challenging owing to microscopical diversity in cell morphology and types of stroma [3, 12] . However, several studies showed that well-circumscribed margins and multinodular growth of spindled and plasmacytoid cells with eccentric nuclei in myxoid, hyalinized or chondroid stroma could be hallmarks for this benign tumor [3, 5, 15] . In contrast, myoepithelial carcinomas are characterized by infiltrative or destructive growth pattern and large cells with irregular and enlarged nuclei embedded in abundant extracellular myxoid matrix. Focal necrosis and large polyhedral cells can also be seen [16] . In the demonstrated case, biopsy revealed a monotonous neoplasm with myoepithelial-type cells and structure that suggested pancreatic myoepithelioma. Postoperative pathology confirmed the diagnosis of STM after assessment of a tumor with well-defined margins and multifocal growth of monotonous spindle cells with focal plasmacytoid morphology and cartilaginous differentiation (Fig. 3a, b) . There was no histological evidence indicating that the STM originated from the pancreas.
Considering the challenges of STM microscopic evaluation, the immunohistochemical (IHC) analysis is critical for proper diagnosis. In two large studies, the most sensitive markers for these tumors were keratin AE/1-AE/3 or pan-keratin (expressed in 93% of cases), vimentin (100%), S-100 protein (85-87%), calponin (86-100%), epithelial membrane antigen (EMA, 63%) and glial fibrillary acidic protein (GFAP, 46%) [3, 17] . Other authors described co-expression of additional markers: cytokeratin CAM5.2 (93-100%), SMA (36-64%), muscle-actin-specific monoclonal antibody (HHF-35, 20-60%) and p63 (7-45%) [3, 15, 18, 19] . In our case, immunohistochemistry analysis showed diffuse tumor expression of CAM5.2, SMA and S-100 protein (Figs. 4-6 ), but did not show expression of CD117 (c-kit) and CD34, which is consistent with IHC criteria of STM diagnosis. The two last markers are also important for differential diagnosis, as their presence is quite specific for GISTs [20] .
Currently, the role of genetic testing in STM diagnosis is disputable although its molecular profile has been a subject of investigation over the last decade. The most recent data state that up to 45% of STM demonstrate Ewing sarcoma region 1 (EWSR1) gene rearrangement by fluorescence in situ hybridization analysis [15, 17, 21, 22] . Skalova et al have found the EWSR1 translocations to be present in 39% (20/51) of clear cell myoepithelial carcinoma specimens, but their cohort included only salivary gland carcinomas [23] . In case of EWSR1-negative STM 38% harbor the rearrangement of pleomorphic adenoma gene 1 (PLAG1) and a small subset of STM (9%) show fused in sarcoma (FUS) gene alterations [24, 25] . Thus, today the data are not sufficient to consider any genetic finding as a reliable diagnostic tool for STM [15] [16] [17] 26] . Therefore, our genetic counselors decided not to perform molecular testing in this patient.
The pretreatment diagnosis of STM in our clinical case remained controversial even after testing, since we saw a combination of benign (absence of invasion and metastases on CT, biopsy results) and malignant (tumor size, left-sided portal hypertension, patchy F-18 FDG uptake on PET-CT) clinical signs. Eventually, this case was considered as a pancreatic potentially malignant myoepithelioma requiring surgery. The tumor compression of SMV and splenic vein junction with left-sided portal hypertension seen during the surgery was suspicious for malignant behavior. Also, a severe peritumoral inflammatory reaction complicated visualization and made it impossible to determine whether or not the tumor was originally pancreatic. Considering the intraoperative findings and suspected malig- Retroperitoneal Soft-Tissue Myoepithelioma J Med Cases. 2020;11(1): [16] [17] [18] [19] [20] [21] nant pattern of tumor, the patient underwent distal pancreatectomy with splenectomy and lymph node dissection. Surgical resection with complete removal (R0 status) is a preferable treatment option of STM. Incomplete resection significantly increases risks of recurrence even in benign myoepitheliomas [3, 12] . The vast majority of these tumors show a favorable prognosis and low incidence of distant metastases [3, 15] . Nonetheless, in rare cases STM can transform into malignant myoepithelial carcinoma when untreated [27, 28] . Behavior of myoepithelial carcinoma is much more aggressive: the local recurrence rate is 39-42% and development of metastatic disease occurs in up to 52% of patients [3, 15, 18] . The tumor of the described patient was removed completely and assessed lymph nodes were negative for tumor tissue. Fifteen months after treatment, the patient had no complaints and signs of disease recurrence.
Conclusion
This case report demonstrates diagnostic and treatment challenges of a rare tumor with uncommon localization -retroperitoneal STM. We believe our clinical experience will help guide clinicians to the appropriate treatment and reduce the risk of undesirable patient outcomes.
